Reports Q3 revenue $20.5M, consensus $20.93M ..”We delivered $20 M in DANYELZA or naxitamab-gqgk net product sales in the third quarter of 2023, reflecting 59% growth compared to the same period in 2022, as sales continued trending upward since our initial launch,” said Mike Rossi, President and Chief Executive Officer. “Our U.S. commercial team has made excellent progress by penetrating more high-volume Children’s Oncology Group sites while our ex-U.S. partners continue to gain further traction with physicians prescribing DANYELZA across Europe and China for relapsed or refractory high-risk neuroblastoma patients.” Mr. Rossi continued, “Supported by a solid financial foundation, we have advanced our novel SADA radioimmunotherapy platform with the continued execution of our Phase 1 GD2-SADA trial and the recent Investigational New Drug clearance of our CD38-SADA program. With existing cash and cash equivalents anticipated to support our business operations as currently planned into 2027, a growing commercial product in DANYELZA, and a differentiated radioimmunotherapy platform in SADA, we believe Y-mAbs is on a path to potentially transform the treatment paradigm for a variety of cancers and improve patients’ lives.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- YMAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
- Y-mAbs Therapeutics appoints Michael Rossi as CEO
- Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
- Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA